-
Insights into vaccines for elderly individuals: from the impacts of immunosenescence to delivery strategies npj Vaccines (IF 9.2) Pub Date : 2024-04-10 Yingying Hou, Min Chen, Yuan Bian, Yuan Hu, Junlan Chuan, Lei Zhong, Yuxuan Zhu, Rongsheng Tong
-
FcRn regulates antigen presentation in dendritic cells downstream of DEC205-targeted vaccines npj Vaccines (IF 9.2) Pub Date : 2024-04-09 Christophe Macri, Matthew Paxman, Devi Jenika, Xiao Peng Lin, Zahra Elahi, Paul A. Gleeson, Irina Caminschi, Mireille H. Lahoud, Jose A. Villadangos, Justine D. Mintern
-
Recovery from antibody-mediated biliary ductopenia and multiorgan inflammation after COVID-19 vaccination npj Vaccines (IF 9.2) Pub Date : 2024-04-08 Alan Chang, Yung-Ming Jeng, Cheng-Maw Ho, Po-Huang Lee
-
Triple tandem trimer immunogens for HIV-1 and influenza nucleic acid-based vaccines npj Vaccines (IF 9.2) Pub Date : 2024-04-06 Iván del Moral-Sánchez, Edmund G. Wee, Yuejiao Xian, Wen-Hsin Lee, Joel D. Allen, Alba Torrents de la Peña, Rebeca Fróes Rocha, James Ferguson, André N. León, Sylvie Koekkoek, Edith E. Schermer, Judith A. Burger, Sanjeev Kumar, Robby Zwolsman, Mitch Brinkkemper, Aafke Aartse, Dirk Eggink, Julianna Han, Meng Yuan, Max Crispin, Gabriel Ozorowski, Andrew B. Ward, Ian A. Wilson, Tomáš Hanke, Kwinten Sliepen
Recombinant native-like HIV-1 envelope glycoprotein (Env) trimers are used in candidate vaccines aimed at inducing broadly neutralizing antibodies. While state-of-the-art SOSIP or single-chain Env designs can be expressed as native-like trimers, undesired monomers, dimers and malformed trimers that elicit non-neutralizing antibodies are also formed, implying that these designs could benefit from further
-
COVID-19 vaccination induces distinct T-cell responses in pediatric solid organ transplant recipients and immunocompetent children npj Vaccines (IF 9.2) Pub Date : 2024-04-05 Katerina Roznik, Jiashu Xue, Georgia Stavrakis, T. Scott Johnston, Divya Kalluri, Rivka Ohsie, Caroline X. Qin, John McAteer, Dorry L. Segev, Douglas Mogul, William A. Werbel, Andrew H. Karaba, Elizabeth A. Thompson, Andrea L. Cox
Immune responses to COVID-19 vaccination are attenuated in adult solid organ transplant recipients (SOTRs) and additional vaccine doses are recommended for this population. However, whether COVID-19 mRNA vaccine responses are limited in pediatric SOTRs (pSOTRs) compared to immunocompetent children is unknown. Due to SARS-CoV-2 evolution and mutations that evade neutralizing antibodies, T cells may
-
Potent and long-lasting humoral and cellular immunity against varicella zoster virus induced by mRNA-LNP vaccine npj Vaccines (IF 9.2) Pub Date : 2024-04-04 Anannya Bhattacharya, Lonzaric Jan, Olga Burlak, Jilong Li, Ghanshyam Upadhyay, Katherine Williams, Jinhui Dong, Harrison Rohrer, Michelle Pynn, Andrew Simon, Nathan Kuhlmann, Sergei Pustylnikov, Mariane B. Melo, Antu K. Dey
Varicella zoster virus (VZV) is a highly contagious human herpes virus responsible for causing chickenpox (varicella) and shingles (herpes zoster). Despite the approval of a highly effective vaccine, Shingrix®, the global incidence of herpes zoster is increasing and the economic burden to the health care system and society are substantial due to significant loss of productivity and health complications
-
Reverse development of vaccines against antimicrobial-resistant pathogens npj Vaccines (IF 9.2) Pub Date : 2024-04-03 Fabio Bagnoli, Ilaria Galgani, V. Kumaran Vadivelu, Sanjay Phogat
Vaccine R&D is typically a lengthy process taking >10 years. However, vaccines still fail in clinical development because of unreliable animal models or absent immunological correlates of protection. Without a correlate of protection, phase-1 and -2 studies of safety and immunogenicity can fail to predict phase-3 efficacy. Indeed, the history of vaccine development is replete with promising phase-1
-
Transcriptional signature of durable effector T cells elicited by a replication defective HCMV vaccine npj Vaccines (IF 9.2) Pub Date : 2024-04-01 Xiaohua Ye, David J. H. Shih, Zhiqiang Ku, Junping Hong, Diane F. Barrett, Richard E. Rupp, Ningyan Zhang, Tong-Ming Fu, W. Jim Zheng, Zhiqiang An
Human cytomegalovirus (HCMV) is a leading infectious cause of birth defects and the most common opportunistic infection that causes life-threatening diseases post-transplantation; however, an effective vaccine remains elusive. V160 is a live-attenuated replication defective HCMV vaccine that showed a 42.4% efficacy against primary HCMV infection among seronegative women in a phase 2b clinical trial
-
Highly stable and immunogenic CMV T cell vaccine candidate developed using a synthetic MVA platform npj Vaccines (IF 9.2) Pub Date : 2024-03-30 Marcal Yll-Pico, Yoonsuh Park, Joy Martinez, Angelina Iniguez, Mindy Kha, Taehyun Kim, Leonard Medrano, Vu H. Nguyen, Teodora Kaltcheva, Shannon Dempsey, Flavia Chiuppesi, Felix Wussow, Don J. Diamond
Human cytomegalovirus (CMV) is the most common infectious cause of complications post-transplantation, while a CMV vaccine for transplant recipients has yet to be licensed. Triplex, a multiantigen Modified Vaccinia Ankara (MVA)-vectored CMV vaccine candidate based on the immunodominant antigens phosphoprotein 65 (pp65) and immediate-early 1 and 2 (IE1/2), is in an advanced stage of clinical development
-
Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials npj Vaccines (IF 9.2) Pub Date : 2024-03-29 Myra Happe, Amelia R. Hofstetter, Jing Wang, Galina V. Yamshchikov, LaSonji A. Holman, Laura Novik, Larisa Strom, Francis Kiweewa, Salim Wakabi, Monica Millard, Colleen F. Kelley, Sarah Kabbani, Srilatha Edupuganti, Allison Beck, Florence Kaltovich, Tamar Murray, Susanna Tsukerman, Derick Carr, Carl Ashman, Daphne A. Stanley, Aurélie Ploquin, Robert T. Bailer, Richard Schwartz, Fatim Cham, Allan Tindikahwa
-
Genomic analysis of lumpy skin disease virus asian variants and evaluation of its cellular tropism npj Vaccines (IF 9.2) Pub Date : 2024-03-21 Shijie Xie, Lianxin Cui, Zhiyi Liao, Junda Zhu, Shuning Ren, Kang Niu, Hua Li, Fei Jiang, Jiajun Wu, Jie Wang, Jian Wu, Baifen Song, Wenxue Wu, Chen Peng
-
Immunization-induced antigen archiving enhances local memory CD8+ T cell responses following an unrelated viral infection npj Vaccines (IF 9.2) Pub Date : 2024-03-21 Thu A. Doan, Tadg S. Forward, Johnathon B. Schafer, Erin D. Lucas, Ira Fleming, Aspen Uecker-Martin, Edgardo Ayala, Jenna J. Guthmiller, Jay R. Hesselberth, Thomas E. Morrison, Beth A. Jirón Tamburini
-
An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza npj Vaccines (IF 9.2) Pub Date : 2024-03-21 Man Xing, Gaowei Hu, Xiang Wang, Yihan Wang, Furong He, Weiqian Dai, Xinyu Wang, Yixin Niu, Jiaojiao Liu, Hui Liu, Xiaoyan Zhang, Jianqing Xu, Qiliang Cai, Dongming Zhou
-
Expansion of memory Vδ2 T cells following SARS-CoV-2 vaccination revealed by temporal single-cell transcriptomics npj Vaccines (IF 9.2) Pub Date : 2024-03-20 Sara Terzoli, Paolo Marzano, Valentina Cazzetta, Rocco Piazza, Inga Sandrock, Sarina Ravens, Likai Tan, Immo Prinz, Simone Balin, Michela Calvi, Anna Carletti, Assunta Cancellara, Nicolò Coianiz, Sara Franzese, Alessandro Frigo, Antonio Voza, Francesca Calcaterra, Clara Di Vito, Silvia Della Bella, Joanna Mikulak, Domenico Mavilio
-
Design of hepadnavirus core protein-based chimeric virus-like particles carrying epitopes from respiratory syncytial virus npj Vaccines (IF 9.2) Pub Date : 2024-03-19 Shuai Shao, Xue Feng Zhang, Jun Wei Hou, Sen Sen Yang, Zi Bo Han, Hai Lan Wu, Fang Tang, Xin Yu Li, Ze Hua Lei, Zi Xin Zhao, Shu Xiang Li, Zhao Ming Liu, Pu Shan, Yu Qin Jin, Ji Guo Su, Yu Liang, Jing Zhang, Qi Ming Li
-
Recent progress on gene-deleted live-attenuated African swine fever virus vaccines npj Vaccines (IF 9.2) Pub Date : 2024-03-13 Hiep L. X. Vu, D. Scott McVey
African Swine Fever (ASF) is a highly lethal viral disease in swine, with mortality rates approaching 100%. The disease has spread to many swine-producing countries, leading to significant economic losses and adversely impacting global food security. Extensive efforts have been directed toward developing effective ASF vaccines. Among the vaccinology approaches tested to date, live-attenuated virus
-
Human immunoglobulin gene allelic variation impacts germline-targeting vaccine priming npj Vaccines (IF 9.2) Pub Date : 2024-03-11 Allan C. deCamp, Martin M. Corcoran, William J. Fulp, Jordan R. Willis, Christopher A. Cottrell, Daniel L. V. Bader, Oleksandr Kalyuzhniy, David J. Leggat, Kristen W. Cohen, Ollivier Hyrien, Sergey Menis, Greg Finak, Lamar Ballweber-Fleming, Abhinaya Srikanth, Jason R. Plyler, Farhad Rahaman, Angela Lombardo, Vincent Philiponis, Rachael E. Whaley, Aaron Seese, Joshua Brand, Alexis M. Ruppel, Wesley
-
Enhanced attenuation of chikungunya vaccines expressing antiviral cytokines npj Vaccines (IF 9.2) Pub Date : 2024-03-12 Christina Chuong, Chelsea N. Cereghino, Pallavi Rai, Tyler A. Bates, Megan Oberer, James Weger-Lucarelli
-
Antigen identification strategies and preclinical evaluation models for advancing tuberculosis vaccine development npj Vaccines (IF 9.2) Pub Date : 2024-03-09 Saurabh Chugh, Ritika Kar Bahal, Rohan Dhiman, Ramandeep Singh
-
BCG-booster vaccination with HSP90-ESAT-6-HspX-RipA multivalent subunit vaccine confers durable protection against hypervirulent Mtb in mice npj Vaccines (IF 9.2) Pub Date : 2024-03-08 Kee Woong Kwon, Han-Gyu Choi, Kwang Sung Kim, Shin Ae Park, Hwa-Jung Kim, Sung Jae Shin
-
Immune response induced by standard and fractional doses of 17DD yellow fever vaccine npj Vaccines (IF 9.2) Pub Date : 2024-03-08 Thais Abdala-Torres, Ana Carolina Campi-Azevedo, Rosiane Aparecida da Silva-Pereira, Luara Isabela dos Santos, Priscilla Miranda Henriques, Ismael Artur Costa-Rocha, Dayane Andriotti Otta, Vanessa Peruhype-Magalhães, Andréa Teixeira-Carvalho, Márcio Sobreira Silva Araújo, Eder Gatti Fernandes, Helena Keico Sato, Francieli Fontana Sutile Tardetti Fantinato, Carla Magda Allan Santos Domingues, Esper
-
Putative correlates of protection against shigellosis assessing immunomarkers across responses to S. sonnei investigational vaccine npj Vaccines (IF 9.2) Pub Date : 2024-03-08 Valentino Conti, Omar Rossi, Kristen A. Clarkson, Francesca Mancini, Usman N. Nakakana, Eleanna Sarakinou, Andrea Callegaro, Pietro Ferruzzi, Alessandra Acquaviva, Ashwani Kumar Arora, Elisa Marchetti, Francesca Necchi, Robert W. Frenck, Laura B. Martin, Robert W. Kaminski, Audino Podda, Francesca Micoli
-
Modulating the immune response to SARS-CoV-2 by different nanocarriers delivering an mRNA expressing trimeric RBD of the spike protein: COVARNA Consortium npj Vaccines (IF 9.2) Pub Date : 2024-03-06 Laura Marcos-Villar, Beatriz Perdiguero, Shubaash Anthiya, Mireya L. Borrajo, Gustavo Lou, Lorenzo Franceschini, Ignasi Esteban, Pedro J. Sánchez-Cordón, Carmen Zamora, Carlos Óscar S. Sorzano, Luis Jordá, Laia Codó, Josep L. Gelpí, Marta Sisteré-Oró, Andreas Meyerhans, Kris Thielemans, Francisco Martínez-Jiménez, Nuria López-Vigas, Felipe García, María J. Alonso, Montserrat Plana, Mariano Esteban
-
A register and questionnaire study of long-term general health symptoms following SARS-CoV-2 vaccination in Denmark npj Vaccines (IF 9.2) Pub Date : 2024-03-04 Elisabeth O’Regan, Ingrid Bech Svalgaard, Anna Irene Vedel Sørensen, Lampros Spiliopoulos, Peter Bager, Nete Munk Nielsen, Jørgen Vinsløv Hansen, Anders Koch, Inger Kristine Meder, Poul Videbech, Steen Ethelberg, Anders Hviid
-
Prospective cohort study evaluating the association between influenza vaccination and neurodegenerative diseases npj Vaccines (IF 9.2) Pub Date : 2024-03-02 Houyu Zhao, Xuan Zhou, Kexin Fu, Yunxiao Duan, Qiaorui Wen, Shengfeng Wang, Siyan Zhan
-
Immune persistence after different polio sequential immunization schedules in Chinese infants npj Vaccines (IF 9.2) Pub Date : 2024-02-29 Ting Zhao, Jing Li, Teng Huang, Zhi-Fang Ying, Yan-Chun Che, Zhi-Mei Zhao, Yu-Ting Fu, Jun-Hui Tao, Qing-Hai Yang, Ding-Kai Wei, Guo-Liang Li, Li Yi, Yu-Ping Zhao, Hong-Bo Chen, Jian-Feng Wang, Rui-Ju Jiang, Lei Yu, Wei Cai, Wei Yang, Ming-Xue Xie, Qiong-Zhou Yin, Jing Pu, Li Shi, Chao Hong, Yan Deng, Lu-Kui Cai, Jian Zhou, Yu Wen, Hong-Sen Li, Wei Huang, Zhao-Jun Mo, Chang-Gui Li, Qi-Han Li, Jing-Si
-
Changes in vaccine attitudes and recommendations among US Healthcare Personnel during the COVID-19 pandemic npj Vaccines (IF 9.2) Pub Date : 2024-02-28 Matthew Z. Dudley, Holly B. Schuh, Amanda Forr, Jana Shaw, Daniel A. Salmon
-
Immunisation efficacy of a stabilised SARS-CoV-2 spike glycoprotein in two geriatric animal models npj Vaccines (IF 9.2) Pub Date : 2024-02-27 Carla Usai, Erola Ainsua-Enrich, Victor Urrea Gales, Edwards Pradenas, Cristina Lorca-Oró, Ferran Tarrés-Freixas, Núria Roca, Mónica Pérez, Carlos Ávila-Nieto, María Luisa Rodríguez de la Concepción, Núria Pedreño-Lopez, Julieta Carabelli, Benjamin Trinité, Ester Ballana, Eva Riveira-Muñoz, Nuria Izquierdo-Useros, Bonaventura Clotet, Julià Blanco, Victor Guallar, Guillermo Cantero, Júlia Vergara-Alert
-
MVA-based vaccines are protective against lethal eastern equine encephalitis virus aerosol challenge in cynomolgus macaques npj Vaccines (IF 9.2) Pub Date : 2024-02-27 Brandon J. Beddingfield, Kenneth S. Plante, Jessica A. Plante, Scott C. Weaver, Sarah Bose, Clara Krzykwa, Nicole Chirichella, Rachel K. Redmann, Stephanie Z. Seiler, Jason Dufour, Robert V. Blair, Kathrin Endt, Ariane Volkmann, Nicholas J. Maness, Chad J. Roy
-
Impact of sex on humoral immunity with live influenza B virus vaccines in mice npj Vaccines (IF 9.2) Pub Date : 2024-02-26 Stivalis Cardenas-Garcia, C. Joaquín Cáceres, Aarti Jain, Ginger Geiger, Jong-Suk Mo, L. Claire Gay, Brittany Seibert, Algimantas Jasinskas, Rie Nakajima, Daniela S. Rajao, D. Huw Davies, Daniel R. Perez
-
Conserved molecular chaperone PrsA stimulates protective immunity against group A Streptococcus npj Vaccines (IF 9.2) Pub Date : 2024-02-26 Chien-Yu Lai, Jia-Xun Xie, Meng-Chih Lai, Zhao-Yi Wu, Jr-Shiuan Lin, Yu-Tsung Huang, Chia-Yu Chi, Chuan Chiang-Ni, Mark J. Walker, Yung-Chi Chang
-
Inter-epitope spacer variation within polytopic L2-based human papillomavirus antigens affects immunogenicity npj Vaccines (IF 9.2) Pub Date : 2024-02-24 Yueru Zhang, Filipe Colaco Mariz, Peter Sehr, Gloria Spagnoli, Karl Moritz Koenig, Simay Çelikyürekli, Tim Kreuziger, Xueer Zhao, Angelo Bolchi, Simone Ottonello, Martin Müller
-
Durable cross-protective neutralizing antibody responses elicited by lipid nanoparticle-formulated SARS-CoV-2 mRNA vaccines npj Vaccines (IF 9.2) Pub Date : 2024-02-23 Ki Hyun Bae, Bhuvaneshwari Shunmuganathan, Li Zhang, Andrew Lim, Rashi Gupta, Yanming Wang, Boon Lin Chua, Yang Wang, Yue Gu, Xinlei Qian, Isabelle Siang Ling Tan, Kiren Purushotorman, Paul A. MacAry, Kevin P. White, Yi Yan Yang
-
Exploring synergies between B- and T-cell vaccine approaches to optimize immune responses against HIV—workshop report npj Vaccines (IF 9.2) Pub Date : 2024-02-21 Milton Maciel, Rama R. Amara, Katharine J. Bar, Shane Crotty, Steven G. Deeks, Christopher Duplessis, Gaurav Gaiha, M. Juliana McElrath, Andrew McMichael, Amy Palin, Rachel Rutishauser, Stuart Shapiro, Stephen T. Smiley, M. Patricia D’Souza
-
No link between type I interferon autoantibody positivity and adverse reactions to COVID-19 vaccines npj Vaccines (IF 9.2) Pub Date : 2024-02-22 Ahmet Yalcinkaya, Marco Cavalli, Axel Cederholm, Maribel Aranda-Guillén, Anish Behere, Hedvig Mildner, Tadepally Lakshmikanth, Laura Gonzalez, Constantin Habimana Mugabo, Anette Johnsson, Olov Ekwall, Olle Kämpe, Sophie Bensing, Petter Brodin, Pär Hallberg, Mia Wadelius, Nils Landegren
-
A phase III randomized-controlled study of safety and immunogenicity of DTwP-HepB-IPV-Hib vaccine (HEXASIIL®) in infants npj Vaccines (IF 9.2) Pub Date : 2024-02-22 Hitt Sharma, Sameer Parekh, Pramod Pujari, Sunil Shewale, Shivani Desai, Anand Kawade, Sanjay Lalwani, M. D. Ravi, Veena Kamath, Jagannath Mahopatra, Ganesh Kulkarni, Deepak Tayade, Padmasani Venkat Ramanan, Kheya Ghosh Uttam, Lalit Rawal, Avinash Gawande, N. Ravi Kumar, Nishikant Tiple, Jayant Vagha, Pareshkumar Thakkar, Prashant Khandgave, Bhaskar Jedhe Deshmukh, Anurag Agarwal, Vikas Dogar, Manish
-
Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine npj Vaccines (IF 9.2) Pub Date : 2024-02-21 David G. Alleva, Eline A. Feitsma, Yester F. Janssen, Hendrikus H. Boersma, Thomas M. Lancaster, Thillainaygam Sathiyaseelan, Sylaja Murikipudi, Andrea R. Delpero, Melanie M. Scully, Ramya Ragupathy, Sravya Kotha, Jeffrey R. Haworth, Nishit J. Shah, Vidhya Rao, Shashikant Nagre, Shannon E. Ronca, Freedom M. Green, Stephen A. Shaw, Ari Aminetzah, Schelto Kruijff, Maarten Brom, Gooitzen M. van Dam, Todd
-
Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth npj Vaccines (IF 9.2) Pub Date : 2024-02-20 Hsuan-Yuan Wang, Leike Li, Cody S. Nelson, Richard Barfield, Sarah Valencia, Cliburn Chan, Hiromi Muramatsu, Paulo J. C. Lin, Norbert Pardi, Zhiqiang An, Drew Weissman, Sallie R. Permar
-
Impact of ageing on homologous and human-coronavirus-reactive antibodies after SARS-CoV-2 vaccination or infection npj Vaccines (IF 9.2) Pub Date : 2024-02-20 Fan Zhou, Juha Vahokoski, Nina Langeland, Rebecca J. Cox
-
Protective efficacy of a Zika purified inactivated virus vaccine candidate during pregnancy in marmosets npj Vaccines (IF 9.2) Pub Date : 2024-02-17 In-Jeong Kim, Olga Gonzalez, Michael P. Tighe, Paula A. Lanthier, Madeline J. Clark, Kelsey L. Travis, Timothy C. Low-Beer, Kathleen G. Lanzer, Derek T. Bernacki, Frank M. Szaba, Rafael A. De La Barrera, Vincent Dussupt, Letzibeth Mendez-Rivera, Shelly J. Krebs, Corinna N. Ross, Stephanie D. Mdaki, Kathleen M. Brasky, Donna Layne-Colon, Suzette D. Tardif, Stephen J. Thomas, Kayvon Modjarrad, Marcia
-
Assessing the impact of mRNA vaccination in chronic inflammatory murine model npj Vaccines (IF 9.2) Pub Date : 2024-02-15 Seonghyun Lee, Jisun Lee, Sun-Hee Cho, Gahyun Roh, Hyo-Jung Park, You-Jeung Lee, Ha-Eun Jeon, Yu-Sun Lee, Seo-Hyeon Bae, Sue Bean Youn, Youngran Cho, Ayoung Oh, Dahyeon Ha, Soo-Yeon Lee, Eun-Jin Choi, Seongje Cho, Sowon Lee, Do-Hyung Kim, Min-Ho Kang, Mee-Sup Yoon, Byung-Kwan Lim, Jae-Hwan Nam
-
Intranasal vaccine for Lyme disease provides protection against tick transmitted Borrelia burgdorferi beyond one year npj Vaccines (IF 9.2) Pub Date : 2024-02-15 Maria Cristina Gingerich, Nisha Nair, Jose F. Azevedo, Kamalika Samanta, Suman Kundu, Biao He, Maria Gomes-Solecki
-
Zika purified inactivated virus (ZPIV) vaccine reduced vertical transmission in pregnant immunocompetent mice npj Vaccines (IF 9.2) Pub Date : 2024-02-15 In-Jeong Kim, Michael P. Tighe, Paula A. Lanthier, Madeline J. Clark, Rafael A. De La Barrera, Vincent Dussupt, Letzibeth Mendez-Rivera, Shelly J. Krebs, Kelsey L. Travis, Timothy C. Low-Beer, Tres S. Cookenham, Kathleen G. Lanzer, Derek T. Bernacki, Frank M. Szaba, Amanda A. Schneck, Jerrold Ward, Stephen J. Thomas, Kayvon Modjarrad, Marcia A. Blackman
-
Risk of carditis among adolescents after extending the interdose intervals of BNT162b2 npj Vaccines (IF 9.2) Pub Date : 2024-02-14 Min Fan, Kuan Peng, Yin Zhang, Francisco Tsz Tsun Lai, Celine Sze Ling Chui, Eric Yuk Fai Wan, Carlos King Ho Wong, Esther Wai Yin Chan, Xue Li, Ian Chi Kei Wong
-
Establishing RTS,S/AS01 as a benchmark for comparison to next-generation malaria vaccines in a mouse model npj Vaccines (IF 9.2) Pub Date : 2024-02-10 Emily Locke, Yevel Flores-Garcia, Bryan T. Mayer, Randall S. MacGill, Bhavesh Borate, Berenice Salgado-Jimenez, Monica W. Gerber, Shamika Mathis-Torres, Sarah Shapiro, C. Richter King, Fidel Zavala
-
Single dose recombinant VSV based vaccine elicits robust and durable neutralizing antibody against Hantaan virus npj Vaccines (IF 9.2) Pub Date : 2024-02-10 Hui Zhang, He Liu, Jing Wei, Yamei Dang, Yuan Wang, Qiqi Yang, Liang Zhang, Chuantao Ye, Bin Wang, Xiaolei Jin, Linfeng Cheng, Hongwei Ma, Yangchao Dong, Yinghui Li, Yinlan Bai, Xin Lv, Yingfeng Lei, Zhikai Xu, Wei Ye, Fanglin Zhang
-
Exploring the future adult vaccine landscape—crowded schedules and new dynamics npj Vaccines (IF 9.2) Pub Date : 2024-02-09 Charles H. Jones, Matthew P. Jenkins, B. Adam Williams, Verna L. Welch, Jane M. True
-
The scientific journey of a novel adjuvant (AS37) from bench to bedside npj Vaccines (IF 9.2) Pub Date : 2024-02-08 Ugo D’Oro, Derek T. O’Hagan
-
Potent induction of humoral and cellular immunity after bivalent BA.4/5 mRNA vaccination in dialysis patients npj Vaccines (IF 9.2) Pub Date : 2024-02-07 Saskia Bronder, Janine Mihm, Rebecca Urschel, Verena Klemis, Tina Schmidt, Stefanie Marx, Amina Abu-Omar, Franziska Hielscher, Candida Guckelmus, Marek Widera, Urban Sester, Martina Sester
-
Intranasal immunization of mice with chimera of Salmonella Typhi protein elicits protective intestinal immunity npj Vaccines (IF 9.2) Pub Date : 2024-02-06 Suparna Chakraborty, Pujarini Dutta, Ananda Pal, Swarnali Chakraborty, George Banik, Prolay Halder, Animesh Gope, Shin-ichi Miyoshi, Santasabuj Das
-
SARS-CoV-2 vaccination may mitigate dysregulation of IL-1/IL-18 and gastrointestinal symptoms of the post-COVID-19 condition npj Vaccines (IF 9.2) Pub Date : 2024-02-05 Claudia Fischer, Edith Willscher, Lisa Paschold, Cornelia Gottschick, Bianca Klee, Sophie Diexer, Lidia Bosurgi, Jochen Dutzmann, Daniel Sedding, Thomas Frese, Matthias Girndt, Jessica I. Hoell, Michael Gekle, Marylyn M. Addo, Julian Schulze zur Wiesch, Rafael Mikolajczyk, Mascha Binder, Christoph Schultheiß
-
Beneficial effect of temporary methotrexate interruption on B and T cell responses upon SARS-CoV-2 vaccination in patients with rheumatoid arthritis or psoriatic arthritis npj Vaccines (IF 9.2) Pub Date : 2024-01-30 Pedro Martínez-Fleta, Esther F. Vicente-Rabaneda, Ana Triguero-Martínez, Emilia Roy-Vallejo, Miren Uriarte-Ecenarro, Francisco Gutiérrez-Rodríguez, Patricia Quiroga-Colina, Ana Romero-Robles, Nuria Montes, Noelia García-Castañeda, Gina P. Mejía-Abril, Jesús A. García-Vadillo, Irene Llorente-Cubas, José R. Villagrasa, José M. Serra López-Matencio, Julio Ancochea, Ana Urzainqui, Laura Esparcia-Pinedo
-
A therapeutic hepatitis B mRNA vaccine with strong immunogenicity and persistent virological suppression npj Vaccines (IF 9.2) Pub Date : 2024-02-03 Huajun Zhao, Xianyu Shao, Yating Yu, Lulu Huang, Narh Philip Amor, Kun Guo, Changzhen Weng, Weijun Zhao, Ailu Yang, Jiesen Hu, Hongbao Yang, Zhenguang Liu, Qiuju Han, Leilei Shi, Shiyu Sun, Jian Zhang, Ang Lin, Yong Yang
-
MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans npj Vaccines (IF 9.2) Pub Date : 2024-01-26 Leonie Mayer, Leonie M. Weskamm, Anahita Fathi, Maya Kono, Jasmin Heidepriem, Verena Krähling, Sibylle C. Mellinghoff, My Linh Ly, Monika Friedrich, Svenja Hardtke, Saskia Borregaard, Thomas Hesterkamp, Felix F. Loeffler, Asisa Volz, Gerd Sutter, Stephan Becker, Christine Dahlke, Marylyn M. Addo
-
In vivo assembly of epitope-coated biopolymer particles that induce anti-tumor responses npj Vaccines (IF 9.2) Pub Date : 2024-01-23 Devi Jenika, Saranya Pounraj, David Wibowo, Leonhard M. Flaxl, Bernd H. A. Rehm, Justine D. Mintern
-
The dengue-specific immune response and antibody identification with machine learning npj Vaccines (IF 9.2) Pub Date : 2024-01-20 Eriberto Noel Natali, Alexander Horst, Patrick Meier, Victor Greiff, Mario Nuvolone, Lmar Marie Babrak, Katja Fink, Enkelejda Miho
-
Development and use of machine learning algorithms in vaccine target selection npj Vaccines (IF 9.2) Pub Date : 2024-01-20 Barbara Bravi
-
Three immunizations with Novavax’s protein vaccines increase antibody breadth and provide durable protection from SARS-CoV-2 npj Vaccines (IF 9.2) Pub Date : 2024-01-20 Klara Lenart, Rodrigo Arcoverde Cerveira, Fredrika Hellgren, Sebastian Ols, Daniel J. Sheward, Changil Kim, Alberto Cagigi, Matthew Gagne, Brandon Davis, Daritza Germosen, Vicky Roy, Galit Alter, Hélène Letscher, Jérôme Van Wassenhove, Wesley Gros, Anne-Sophie Gallouët, Roger Le Grand, Harry Kleanthous, Mimi Guebre-Xabier, Ben Murrell, Nita Patel, Gregory Glenn, Gale Smith, Karin Loré
-
Neoantigen vaccine nanoformulations based on Chemically synthesized minimal mRNA (CmRNA): small molecules, big impact npj Vaccines (IF 9.2) Pub Date : 2024-01-18 Saber Imani, Oya Tagit, Chantal Pichon
-
Bringing immunofocusing into focus npj Vaccines (IF 9.2) Pub Date : 2024-01-09 Sriharshita Musunuri, Payton A. B. Weidenbacher, Peter S. Kim